Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial - Aisen, Paul S; Thal, Leon J; Ferris, Steven H; Assaid, Christopher; Nessly, Michael L; Giuliani, Michael J; Lines, Christopher R; Norman, Barbara A; Potter, William Z (Current Alzheimer research, 2008)
Keywords: Alzheimer Disease - diagnosis; Alzheimer Disease - etiology; Alzheimer Disease - prevention & control; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Cognition Disorders - complications; Cognition Disorders - drug therapy; Cyclooxygenase 2 Inhibitors - adverse effects; Cyclooxygenase 2 Inhibitors - therapeutic use; Disease Progression; Double-Blind Method; Humans; Lactones - adverse effects; Lactones - therapeutic use; Proportional Hazards Models; Risk Assessment; Sulfones - adverse effects; Sulfones - therapeutic use; Treatment Failure